Vasculitis & polymyalgia rheumatica
Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement
Authors' conclusion
Our findings indicate that ICI-PMR may have a milder course with less intense inflammation than primary PMR.
Study context
- Population
- Patients with ICI-mediated PMR (with cancer) and patients with primary PMR
- Participants
- 15 vs 37
- Exposure
- ICI-mediated PMR vs primary PMR
- ICI-PMRn = 15
- Primary PMRn = 37reference
- Outcome
- Clinical characteristics, imaging findings and treatment requirements
Methodological detailssingle centre
- Single centre
Main finding
As reported in the abstract
- Fulfilled EULAR/ACR classification criteria for PMR: ICI-PMR 66.7% vs primary PMR 97.3%
- Morning stiffness, weight loss and ESR elevation less frequent in ICI-PMR
- No differences in inflammatory lesions on US of shoulders and hips
- Leuven and Leuven/Groningen 18F-FDG-PET/CT scores significantly lower in ICI-PMR
- ICI-PMR managed with lower GC doses, discontinued more quickly
Observational data: associations, not effects.
Original publication
Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Rheumatology (Oxford). Published 9 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →